PULMOSMART 200 120MD (Budesonide 200 mcg+Ethanol 0.5 %+Formoterol 6 mcg)

The PULMOSMART 200 INHALER is formulated with Budesonide and Formoterol, classified as inhaled corticosteroids and long-acting beta-adrenergic agonists. It is indicated for both adults and children aged six years and older for the continuous management of asthma and moderate to severe Chronic Obstructive Pulmonary Disease (COPD) that presents with frequent symptoms and a history of episodes of worsening condition. Asthma is characterized by the narrowing and inflammation of the airways, leading to excess mucus production, resulting in symptoms such as shortness of breath, coughing, wheezing, and sputum production. Meanwhile, COPD is a long-lasting inflammatory lung condition that obstructs airflow. Prior to initiating treatment with PULMOSMART 200 INHALER, healthcare professionals may conduct specific respiratory assessments to evaluate the severity of the patient’s respiratory issues and lung function. The growth of children using this inhaler will be regularly monitored by their healthcare provider. It is important to note that this inhaler should not be used by individuals allergic to its components. The use of PULMOSMART 200 INHALER during pregnancy or while nursing is generally discouraged unless it is deemed absolutely necessary by a physician. Patients should disclose any pre-existing conditions such as cardiovascular issues, hypertension, seizures, diabetes, thyroid disorders, liver conditions, osteoporosis, autoimmune diseases, ocular issues like glaucoma or cataracts, and any recent exposure to infectious diseases prior to using this medication. The inhaler is contraindicated for children below the age of six. The reported side effects can include muscle discomfort, sleep disturbances, heart palpitations, elevated heart rate, increased blood sugar, and lower potassium levels. It is advisable for patients to consult their healthcare provider if they experience any worsening or persistent symptoms.